Key Takeaways ABBV offset Humira's LOE as Skyrizi & Rinvoq delivered $18.5B combined sales in the first nine months of 2025.MRK's Keytruda drove growth with $23.3B in sales in the first nine months of 2025.ABBV shares rose 26.6% over the past year as ex-Humira drugs fueled renewed revenue growth.Merck (MRK) and AbbVie (ABBV) are leading pharmaceutical players with entrenched franchises in oncology and immunology. Beyond these core areas, AbbVie has built a presence in aesthetics, neuroscience and eye care, ...

Key Points AbbVie and Coca-Cola are blue-chip stocks that have excellent financials. These two stocks proved resilient in 2022, rising in value while the markets crashed. They are both Dividend Kings, with excellent track records for raising their payouts. 10 stocks we like better than AbbVie › If you're a retiree, you may be concerned about how safe it is to invest in the stock market right now. Valuations are high, economic conditions are questionable, and it's getting more difficult to find qua ...

此次获批新适应症是基于INSPIRE和COMMAND两项III期临床试验的积极结果。 结果显示，在INSPIRE诱导治疗试验中，与安慰剂相比，利生奇珠单抗治疗12周显著提高了临床缓解率 (20.3%vs6.2%;调整后组间差异14.0%[95%CI：10.0%–18.0%];P<0.001);在COMMAND维持治疗试验中， 180mg和360mg两种维持剂量治疗52周的临床缓解率均显著优于安慰剂组(40.2%vs37.6%vs25.1%)。 2025年3月10日，利生奇珠单抗在中国首次获批上市，用于治疗对传统治疗或生物制剂治疗应答不足、 失应答或不耐受的中重度活动性克罗恩病成年患者。 1月22日，艾伯维(ABBV.US)宣布利生奇珠单抗(risankizumab，商品名：喜开悦)在华获批第二项适应 症，用于治疗对传统治疗或生物制剂治疗应答不足、失应答或不耐受的中重度活动性溃疡性结肠炎 (UC)成年患者。 利生奇珠单抗是一种IL-23抑制剂，可通过与IL-23p19亚基结合来选择性阻断IL-23。IL-23是一种参与炎 症过程的细胞因子，被认为与许多慢性免疫介导疾病有关。 ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug licensed from Danish biotech Gubra. Emphasizing differen ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug licensed from Danish biotech Gubra. Emphasizing differen ...

创业板指冲高回落涨0.54%、科创50涨超3.5%，半导体产业链全线爆发。锋龙股份16连板，广电电气4连板，一图看懂>> 红 宝 丽 2天2板 公司主要从事环氧丙烷衍生品,一异丙醇胺可用于电子化学品之光刻胶清洗剂,也是近 年来公司在国内市场重点拓展的应用领域之一 AIET AI4S推动创新药发展;荣昌生物与艾伯维达成超50亿美元BD 澳佳华 旗下AI按摩机器人运用了语音交互、人脸识别、智能生理参数检测等技术，还接入 DeepSeek,打造健康生态AI大模型 液晶面板/LCD 三利谱 国内偏光片行业龙头企业之一,国内少数具备TFT-LCD用偏光片生产能力的企业之一, 是华为等全球著名终端品牌显示屏材料供应商 深纺织A 深圳国资委控股的纺织集团旗下,主营液晶显示用偏光片 人工智能大模型 DeepSeek或2月发布新一代旗舰模型,具备强大编程能力 环球印务 子公司领凯科技逐步引入ChatGPT技术,在数字化广告营销中为广告智能投放、素材自 动化创作、直播带货业务场景及智能对话客服等方面赋能 房地产 住建部部长:今年将着力稳定房地产市场,支持房企合理的融资需求 德才股份 6天3板 山东省唯一建筑装饰上市企业,主业覆盖 ...

ADC已成为当前创新药领域最具确定性的治疗策略之一。 在今年的摩根大通医疗健康大会上，多家MNC在研发规划中明确将ADC纳入核心技术平台——无论是单药研发还是联合治疗方案，ADC在肿瘤管线中的 权重持续提升，成为巨头布局的核心方向。 不过，进步空间仍然巨大。一方面，实现精准治疗的疾病仍只是少数；另一方面，即便是精准治疗，仍面临疗效、依从性、安全性等一系列问题。 因此，当前自免领域仍存在真正未被满足的需求。更精准且长期可持续的免疫调节是 "下一代" 自免药物的追求，ADC 在这一背景下显得尤为具有潜力。 与肿瘤领域强调 "细胞清除" 不同，自免 ADC 的核心是通过靶向特定表型的免疫细胞（如自身反应性B细胞或T细胞），将有效载荷精准递送到致病免疫 细胞，既能抑制炎症反应，又尽量保留整体免疫功能。 这种高靶向性和功能性去除的理念，意味着自免 ADC 同时具备更高疗效和更低系统毒性。 但ADC的潜力上限，远不止于肿瘤领域。从治疗逻辑来看，ADC"精准靶向+强效杀伤"的特性，恰好契合了自身免疫性疾病对"精准干预、长期控制"的核 心需求。 事实上，自免ADC的探索早已启动。作为全球自免领域的龙头企业，艾伯维率先迈出尝试 ...

In an uncertain and volatile market, dividend stocks are often the first choice for investors looking for reliable income. Companies that have a stable business model tend to consistently pay dividends, offering stability and predictability. Here are three such reliable dividend stocks that investors can hold onto for years. More News from Barchart Reliable Stock No. 1: AbbVie (ABBV) Valued at $383 billion, AbbVie (ABBV) is a global biopharmaceutical company that discovers, develops, and sells medicin ...

All three of these healthcare giants are leaders in their niches.Healthcare-focused investors may be disappointed to learn that the sector underperformed the broader market last year. However, they might also appreciate the fact that there are plenty of stocks in the industry that appear to be excellent buy-and-hold options.Let's consider three of them: Eli Lilly (LLY +0.52%), AbbVie (ABBV 0.31%), and Intuitive Surgical (ISRG 1.15%). Here's why, for those looking to put $5,000 in equity markets right now, t ...

Investment Rating - The report indicates a positive investment outlook for the innovative drug sector, particularly focusing on the advancements in T-cell engagers (TCE) for multiple myeloma (MM) treatment [1]. Core Insights - Johnson & Johnson's teclistamab has shown significant efficacy in the treatment of relapsed or refractory multiple myeloma (r/r MM), with a 71% reduction in disease progression or death risk and a 40% reduction in mortality risk compared to standard treatments [14][15]. - The report highlights the unmet medical needs in the MM treatment landscape, emphasizing the potential of TCE therapies targeting BCMA and GPRC5D to improve patient outcomes [9][10]. - The ongoing clinical trials and approvals for various TCE therapies, including teclistamab and talquetamab, are expected to reshape the treatment paradigm for MM, particularly in patients who have undergone multiple lines of therapy [28][34]. Summary by Sections Innovative Drug Focus - The report reviews the recent developments in innovative drugs, particularly in the context of TCE therapies for blood cancers, with a focus on their expanding applications beyond hematological malignancies [5][7]. TCE Therapy Developments - TCE therapies have gained traction in the treatment of MM, with several candidates achieving FDA approval for patients who have received multiple prior therapies. The overall response rates (ORR) for these therapies range from 60% to 74% [9][10]. - The report details the clinical trial results for teclistamab, which has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) in r/r MM patients [14][21]. Market Potential - The report estimates that the sales for teclistamab in China could reach approximately $5.49 billion by 2024, indicating a strong market potential for TCE therapies in the region [6]. - The ongoing research and development efforts in TCE therapies are expected to address the significant unmet needs in the MM treatment landscape, with a focus on improving patient outcomes and survival rates [9][10].